New Developments on Thromboxane and Prostacyclin Modulators Part I: Thromboxane Modulators
Authors: Dogne, Jean-Michel; Leval, Xavier d.; Hanson, Julien; Frederich, Michel; Lambermont, Bernard; Ghuysen, Alexandre; Casini, Angela; Masereel, Bernard; Ruan, Ke-He; Pirotte, Bernard; Kolh, Philippe
Source: Current Medicinal Chemistry, Volume 11, Number 10, May 2004 , pp. 1223-1241(19)
Publisher: Bentham Science Publishers
Abstract:The pathogenesis of numerous cardiovascular, pulmonary, inflammatory, and thromboembolic diseases can be related to arachidonic acid (AA) metabolites. One of these bioactive metabolites of particular importance is thromboxane A2 (TXA2). It is produced by the action of thromboxane synthase on the prostaglandin endoperoxide H2 (PGH2), which results from the enzymatic degradation of AA by the cyclooxygenases. TXA2 is a potent inducer of platelet aggregation, vasoconstriction and bronchoconstriction. It is involved in a series of major pathophysiological states such as asthma, myocardial ischemia, pulmonary hypertension, and thromboembolic disorders. Therefore, TXA2 receptor antagonists, thromboxane synthase inhibitors and drugs combining both properties have been developed by several pharmaceutical companies since the early 1980s. Several compounds have been launched on the market and others are under clinical evaluation. Moreover, the recent literature reported the interest of thromboxane modulators, which combine another pharmacological activity such as, platelet activating factor antagonism, angiotensin II antagonism, or 5-lipoxygenase inhibition. In this review, we will propose a description of the recently described thromboxane modulators of major interest from both a pharmacological and a chemical point of view.
Document Type: Review Article
Affiliations: Natural and Synthetic Drug Research Centre, Medicinal Chemistry, University of Liege, 1, av. De l'Hopital, B-4000 Liege, Belgium.
Publication date: May 1, 2004
- Current Medicinal Chemistry covers all the latest and outstanding developments in medicinal chemistry and rational drug design. Each issue contains a series of timely in-depth reviews written by leaders in the field covering a range of the current topics in medicinal chemistry. Current Medicinal Chemistry is an essential journal for every medicinal chemist who wishes to be kept informed and up-to-date with the latest and most important developments.